Tracking 'Living Drug' cells to improve cancer treatment
NCT ID NCT05366569
Summary
This study aims to better understand how CAR-T cell therapy works in patients with specific blood cancers (lymphoma and leukemia) in real-world settings. Researchers will closely monitor how long the modified immune cells last in the body and how well they fight the cancer. They will also study biological markers to predict treatment response and identify potential side effects, particularly neurological complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASST Spedali Civili di Brescia
RECRUITINGBrescia, 25123, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.